| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 55 | 2023 | 210 | 8.140 |
Why?
|
| Rhinitis | 44 | 2023 | 175 | 6.810 |
Why?
|
| Rhinitis, Allergic, Seasonal | 43 | 2017 | 179 | 5.670 |
Why?
|
| Rhinitis, Allergic, Perennial | 24 | 2023 | 81 | 3.660 |
Why?
|
| Tonsillectomy | 8 | 2023 | 30 | 3.660 |
Why?
|
| Nasal Polyps | 18 | 2023 | 58 | 3.520 |
Why?
|
| Nasal Mucosa | 44 | 2016 | 186 | 2.910 |
Why?
|
| Rhinitis, Allergic | 11 | 2024 | 43 | 2.850 |
Why?
|
| Nasal Provocation Tests | 36 | 2023 | 129 | 2.720 |
Why?
|
| Hypersensitivity | 19 | 2024 | 154 | 2.650 |
Why?
|
| Sleep Apnea, Obstructive | 8 | 2023 | 219 | 2.510 |
Why?
|
| Allergens | 30 | 2024 | 179 | 2.370 |
Why?
|
| Adenoidectomy | 9 | 2023 | 23 | 2.160 |
Why?
|
| Androstadienes | 9 | 2013 | 72 | 2.110 |
Why?
|
| Nose | 11 | 2022 | 94 | 1.800 |
Why?
|
| Anti-Allergic Agents | 13 | 2015 | 39 | 1.790 |
Why?
|
| Sleep Apnea, Central | 2 | 2022 | 14 | 1.660 |
Why?
|
| Paranasal Sinuses | 13 | 2021 | 60 | 1.470 |
Why?
|
| Eosinophils | 18 | 2013 | 194 | 1.440 |
Why?
|
| Anti-Inflammatory Agents | 12 | 2016 | 339 | 1.300 |
Why?
|
| Maxillary Sinusitis | 4 | 2015 | 16 | 1.300 |
Why?
|
| Humans | 192 | 2024 | 86601 | 1.230 |
Why?
|
| Otolaryngology | 4 | 2023 | 53 | 1.190 |
Why?
|
| Acetates | 5 | 2010 | 66 | 1.190 |
Why?
|
| Eye | 4 | 2013 | 111 | 1.140 |
Why?
|
| Quinolines | 5 | 2010 | 95 | 1.130 |
Why?
|
| Chronic Disease | 30 | 2023 | 970 | 1.110 |
Why?
|
| Endoscopy | 13 | 2022 | 332 | 1.090 |
Why?
|
| Nasal Cavity | 15 | 2014 | 91 | 1.080 |
Why?
|
| Administration, Intranasal | 26 | 2020 | 136 | 1.070 |
Why?
|
| Leukotriene Antagonists | 7 | 2015 | 25 | 1.060 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2022 | 103 | 0.990 |
Why?
|
| Glucocorticoids | 6 | 2015 | 352 | 0.970 |
Why?
|
| Double-Blind Method | 35 | 2016 | 1823 | 0.970 |
Why?
|
| Male | 105 | 2023 | 40956 | 0.960 |
Why?
|
| Tracheotomy | 4 | 2020 | 18 | 0.950 |
Why?
|
| Loratadine | 7 | 2008 | 21 | 0.950 |
Why?
|
| Adrenal Cortex Hormones | 10 | 2023 | 263 | 0.930 |
Why?
|
| Histamine | 11 | 2013 | 126 | 0.920 |
Why?
|
| Ganglioneuroblastoma | 1 | 2023 | 4 | 0.910 |
Why?
|
| Female | 106 | 2023 | 44507 | 0.900 |
Why?
|
| Histamine H1 Antagonists | 7 | 2002 | 40 | 0.870 |
Why?
|
| Cross-Over Studies | 23 | 2016 | 399 | 0.860 |
Why?
|
| Child, Preschool | 23 | 2023 | 3611 | 0.830 |
Why?
|
| Adult | 84 | 2021 | 25640 | 0.830 |
Why?
|
| Ambrosia | 5 | 2012 | 14 | 0.800 |
Why?
|
| Asthma | 13 | 2024 | 955 | 0.790 |
Why?
|
| Terfenadine | 8 | 2004 | 22 | 0.770 |
Why?
|
| Polysomnography | 7 | 2019 | 151 | 0.720 |
Why?
|
| Quality of Life | 23 | 2023 | 1583 | 0.700 |
Why?
|
| Child | 32 | 2021 | 6926 | 0.690 |
Why?
|
| Histamine Release | 9 | 2008 | 53 | 0.690 |
Why?
|
| Mouth Diseases | 1 | 2018 | 15 | 0.660 |
Why?
|
| Immunoglobulin E | 11 | 2018 | 144 | 0.660 |
Why?
|
| Budesonide | 4 | 2014 | 45 | 0.650 |
Why?
|
| Maxillary Sinus | 3 | 2013 | 26 | 0.650 |
Why?
|
| Humidity | 15 | 2008 | 89 | 0.640 |
Why?
|
| Choristoma | 1 | 2018 | 68 | 0.640 |
Why?
|
| Stomach | 1 | 2018 | 108 | 0.630 |
Why?
|
| Cysts | 1 | 2018 | 104 | 0.610 |
Why?
|
| Air | 8 | 2008 | 62 | 0.590 |
Why?
|
| Sneezing | 10 | 2011 | 36 | 0.580 |
Why?
|
| Methyl Ethers | 2 | 2013 | 33 | 0.570 |
Why?
|
| Anesthesia, Inhalation | 2 | 2013 | 36 | 0.570 |
Why?
|
| Anesthesia, Intravenous | 2 | 2013 | 35 | 0.570 |
Why?
|
| Methacholine Chloride | 10 | 2002 | 64 | 0.570 |
Why?
|
| Propofol | 2 | 2013 | 89 | 0.560 |
Why?
|
| Blood Loss, Surgical | 2 | 2013 | 112 | 0.550 |
Why?
|
| Headache | 2 | 2015 | 73 | 0.550 |
Why?
|
| Nasal Decongestants | 4 | 2018 | 10 | 0.530 |
Why?
|
| Ephedrine | 2 | 2006 | 6 | 0.530 |
Why?
|
| Nasal Lavage Fluid | 10 | 2012 | 26 | 0.520 |
Why?
|
| Intestines | 1 | 2018 | 411 | 0.520 |
Why?
|
| Paranasal Sinus Diseases | 3 | 2013 | 25 | 0.510 |
Why?
|
| Treatment Outcome | 21 | 2022 | 7988 | 0.500 |
Why?
|
| Device Removal | 1 | 2015 | 161 | 0.490 |
Why?
|
| Personnel Selection | 1 | 2014 | 59 | 0.480 |
Why?
|
| Anaphylaxis | 2 | 2024 | 33 | 0.480 |
Why?
|
| Osteogenesis, Distraction | 3 | 2020 | 24 | 0.480 |
Why?
|
| Airway Obstruction | 4 | 2020 | 109 | 0.470 |
Why?
|
| Mycoses | 2 | 2014 | 46 | 0.470 |
Why?
|
| Nasal Obstruction | 4 | 2023 | 21 | 0.470 |
Why?
|
| Reflex | 8 | 2013 | 79 | 0.470 |
Why?
|
| Middle Aged | 43 | 2017 | 25017 | 0.470 |
Why?
|
| Eosinophilia | 4 | 2017 | 84 | 0.470 |
Why?
|
| Beclomethasone | 5 | 1998 | 16 | 0.460 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 257 | 0.460 |
Why?
|
| Eye Diseases | 2 | 2011 | 53 | 0.460 |
Why?
|
| Internship and Residency | 3 | 2023 | 1004 | 0.460 |
Why?
|
| Dibenzoxepins | 1 | 2013 | 5 | 0.450 |
Why?
|
| Oxymetazoline | 3 | 2011 | 10 | 0.440 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 369 | 0.440 |
Why?
|
| Mucociliary Clearance | 3 | 2007 | 7 | 0.430 |
Why?
|
| Adolescent | 27 | 2016 | 8979 | 0.420 |
Why?
|
| Desensitization, Immunologic | 7 | 2024 | 36 | 0.420 |
Why?
|
| Abscess | 2 | 2015 | 91 | 0.420 |
Why?
|
| Atropine | 5 | 1996 | 59 | 0.410 |
Why?
|
| Adenoids | 1 | 2011 | 9 | 0.410 |
Why?
|
| Mandible | 4 | 2020 | 119 | 0.400 |
Why?
|
| Ear Diseases | 1 | 2011 | 19 | 0.390 |
Why?
|
| Vitamin D | 2 | 2010 | 261 | 0.380 |
Why?
|
| Interleukins | 1 | 2011 | 134 | 0.380 |
Why?
|
| Postoperative Complications | 5 | 2019 | 2207 | 0.380 |
Why?
|
| Gastroesophageal Reflux | 2 | 2016 | 117 | 0.370 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 3 | 2008 | 13 | 0.370 |
Why?
|
| Carbon Dioxide | 1 | 2011 | 188 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2018 | 2600 | 0.370 |
Why?
|
| Steroids | 3 | 2022 | 177 | 0.370 |
Why?
|
| Respiratory Tract Diseases | 2 | 2001 | 45 | 0.360 |
Why?
|
| Reflex, Abnormal | 1 | 2009 | 5 | 0.350 |
Why?
|
| Drug Therapy, Combination | 7 | 2018 | 894 | 0.350 |
Why?
|
| Pierre Robin Syndrome | 2 | 2020 | 13 | 0.340 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1801 | 0.340 |
Why?
|
| Job Application | 1 | 2008 | 8 | 0.340 |
Why?
|
| Pollen | 7 | 2011 | 80 | 0.340 |
Why?
|
| Lung Diseases | 1 | 2011 | 263 | 0.330 |
Why?
|
| Cytokines | 9 | 2022 | 776 | 0.330 |
Why?
|
| Biological Products | 3 | 2020 | 143 | 0.330 |
Why?
|
| Inhalation | 2 | 2010 | 31 | 0.330 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2008 | 10 | 0.320 |
Why?
|
| Cervical Plexus | 1 | 2007 | 4 | 0.320 |
Why?
|
| Infant | 13 | 2021 | 3045 | 0.320 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2007 | 12 | 0.320 |
Why?
|
| Esophageal Sphincter, Upper | 1 | 2007 | 5 | 0.320 |
Why?
|
| Vagus Nerve | 1 | 2007 | 45 | 0.320 |
Why?
|
| Ipratropium | 5 | 2003 | 18 | 0.320 |
Why?
|
| Staphylococcal Infections | 3 | 2008 | 255 | 0.320 |
Why?
|
| Neurilemmoma | 1 | 2007 | 34 | 0.310 |
Why?
|
| Esophageal Diseases | 1 | 2007 | 26 | 0.310 |
Why?
|
| Phthalazines | 3 | 2008 | 39 | 0.310 |
Why?
|
| Pneumococcal Infections | 6 | 2008 | 46 | 0.310 |
Why?
|
| Evidence-Based Medicine | 5 | 2019 | 429 | 0.310 |
Why?
|
| Cyclopropanes | 5 | 2010 | 25 | 0.300 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 239 | 0.300 |
Why?
|
| Sulfides | 5 | 2010 | 68 | 0.290 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 32 | 0.290 |
Why?
|
| Mast Cells | 4 | 2012 | 92 | 0.280 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2006 | 34 | 0.280 |
Why?
|
| Antigens | 7 | 2001 | 228 | 0.280 |
Why?
|
| Retrospective Studies | 11 | 2021 | 8475 | 0.280 |
Why?
|
| Deglutition | 1 | 2006 | 73 | 0.280 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2014 | 295 | 0.280 |
Why?
|
| Comorbidity | 5 | 2016 | 943 | 0.280 |
Why?
|
| Cell Adhesion Molecules | 3 | 1995 | 163 | 0.270 |
Why?
|
| Infant, Newborn | 8 | 2021 | 2378 | 0.270 |
Why?
|
| Tracheal Neoplasms | 1 | 2005 | 8 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 1034 | 0.270 |
Why?
|
| Papilloma | 1 | 2005 | 22 | 0.270 |
Why?
|
| Hot Temperature | 7 | 2008 | 206 | 0.260 |
Why?
|
| Consensus | 4 | 2023 | 335 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 316 | 0.260 |
Why?
|
| Acute Disease | 6 | 2020 | 826 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 0.260 |
Why?
|
| Laryngeal Neoplasms | 1 | 2005 | 89 | 0.250 |
Why?
|
| Statistics, Nonparametric | 6 | 2019 | 307 | 0.250 |
Why?
|
| Patient Selection | 3 | 2020 | 685 | 0.240 |
Why?
|
| Prospective Studies | 11 | 2021 | 4210 | 0.240 |
Why?
|
| Parotitis | 1 | 2003 | 6 | 0.240 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 263 | 0.240 |
Why?
|
| Temperature | 5 | 2007 | 396 | 0.230 |
Why?
|
| Surveys and Questionnaires | 9 | 2016 | 2501 | 0.230 |
Why?
|
| Iron-Dextran Complex | 1 | 2023 | 1 | 0.230 |
Why?
|
| Bacterial Infections | 2 | 2014 | 182 | 0.230 |
Why?
|
| Women | 1 | 2023 | 25 | 0.230 |
Why?
|
| Papillomaviridae | 2 | 2005 | 153 | 0.230 |
Why?
|
| Fluticasone | 5 | 2010 | 30 | 0.230 |
Why?
|
| Pharynx | 1 | 2023 | 45 | 0.220 |
Why?
|
| Nasal Lavage | 1 | 2022 | 2 | 0.220 |
Why?
|
| Neurogenic Inflammation | 1 | 2002 | 2 | 0.220 |
Why?
|
| Poaceae | 5 | 2011 | 19 | 0.220 |
Why?
|
| Symptom Assessment | 2 | 2020 | 65 | 0.220 |
Why?
|
| Dermatitis, Atopic | 1 | 2003 | 52 | 0.220 |
Why?
|
| Cilia | 2 | 2016 | 29 | 0.220 |
Why?
|
| Serine Endopeptidases | 1 | 2002 | 145 | 0.210 |
Why?
|
| Tongue | 2 | 2016 | 57 | 0.210 |
Why?
|
| Encephalocele | 1 | 2022 | 24 | 0.210 |
Why?
|
| Microbiota | 3 | 2018 | 381 | 0.210 |
Why?
|
| Atmosphere Exposure Chambers | 2 | 2001 | 7 | 0.200 |
Why?
|
| Young Adult | 7 | 2015 | 5974 | 0.200 |
Why?
|
| Speech | 1 | 2021 | 84 | 0.190 |
Why?
|
| Bronchial Provocation Tests | 1 | 2000 | 24 | 0.190 |
Why?
|
| Research | 1 | 2001 | 253 | 0.190 |
Why?
|
| Betacoronavirus | 2 | 2020 | 258 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 105 | 0.180 |
Why?
|
| Lymphangioma | 1 | 1999 | 15 | 0.180 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 42 | 0.180 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 1685 | 0.180 |
Why?
|
| Streptococcal Infections | 2 | 2015 | 57 | 0.180 |
Why?
|
| Pregnadienediols | 3 | 2011 | 13 | 0.180 |
Why?
|
| Bevacizumab | 1 | 2021 | 281 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 57 | 0.180 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 320 | 0.180 |
Why?
|
| Pilot Projects | 3 | 2021 | 839 | 0.180 |
Why?
|
| Child Development | 1 | 2021 | 163 | 0.170 |
Why?
|
| Skin Tests | 3 | 2018 | 44 | 0.170 |
Why?
|
| Capillary Permeability | 3 | 2013 | 130 | 0.170 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 116 | 0.170 |
Why?
|
| Operating Rooms | 1 | 2020 | 126 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 115 | 0.170 |
Why?
|
| Goals | 1 | 2019 | 67 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2005 | 1961 | 0.170 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 21 | 0.170 |
Why?
|
| Inflammation Mediators | 4 | 2003 | 154 | 0.170 |
Why?
|
| Leukocyte Count | 4 | 2012 | 220 | 0.160 |
Why?
|
| Pulmonary Ventilation | 2 | 2011 | 32 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 150 | 0.160 |
Why?
|
| Serum Albumin | 5 | 2002 | 130 | 0.160 |
Why?
|
| Placebos | 4 | 2008 | 218 | 0.160 |
Why?
|
| Mucous Membrane | 4 | 2008 | 83 | 0.160 |
Why?
|
| Complementary Therapies | 2 | 2018 | 54 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 311 | 0.160 |
Why?
|
| Streptococcus pneumoniae | 5 | 2006 | 48 | 0.160 |
Why?
|
| Albumins | 3 | 2008 | 133 | 0.160 |
Why?
|
| Biological Therapy | 1 | 2018 | 45 | 0.160 |
Why?
|
| Olfactory Mucosa | 2 | 2010 | 33 | 0.160 |
Why?
|
| Esophagus | 2 | 2009 | 102 | 0.160 |
Why?
|
| Analysis of Variance | 8 | 2006 | 912 | 0.160 |
Why?
|
| Dilatation | 1 | 2018 | 48 | 0.160 |
Why?
|
| Clemastine | 1 | 1997 | 2 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 579 | 0.150 |
Why?
|
| Allergists | 1 | 2016 | 4 | 0.150 |
Why?
|
| Pandemics | 2 | 2020 | 740 | 0.150 |
Why?
|
| Prognosis | 3 | 2020 | 3674 | 0.150 |
Why?
|
| Prostaglandin D2 | 2 | 1996 | 27 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2018 | 170 | 0.150 |
Why?
|
| Delphi Technique | 3 | 2023 | 80 | 0.150 |
Why?
|
| Cholinergic Antagonists | 2 | 2003 | 26 | 0.150 |
Why?
|
| Antibodies, Anti-Idiotypic | 3 | 2013 | 44 | 0.150 |
Why?
|
| Medical History Taking | 2 | 2013 | 80 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 66 | 0.140 |
Why?
|
| Animals | 14 | 2016 | 26581 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2014 | 746 | 0.140 |
Why?
|
| Leukotriene B4 | 1 | 1996 | 14 | 0.140 |
Why?
|
| Inflammation | 7 | 2015 | 920 | 0.140 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 47 | 0.140 |
Why?
|
| Disease Models, Animal | 5 | 2006 | 2232 | 0.140 |
Why?
|
| Immunotherapy | 3 | 2024 | 629 | 0.140 |
Why?
|
| Eikenella corrodens | 1 | 2015 | 2 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2016 | 65 | 0.140 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 4 | 1998 | 56 | 0.140 |
Why?
|
| Trismus | 1 | 2015 | 6 | 0.140 |
Why?
|
| Respiratory Hypersensitivity | 2 | 1999 | 41 | 0.140 |
Why?
|
| Hypesthesia | 1 | 2015 | 15 | 0.140 |
Why?
|
| Leukocytosis | 1 | 2015 | 16 | 0.140 |
Why?
|
| Cellulose | 1 | 2016 | 55 | 0.140 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2015 | 23 | 0.140 |
Why?
|
| Tachycardia | 1 | 2015 | 35 | 0.140 |
Why?
|
| Muscarinic Antagonists | 1 | 1996 | 55 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2018 | 394 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2016 | 81 | 0.130 |
Why?
|
| Pharyngeal Diseases | 1 | 2015 | 11 | 0.130 |
Why?
|
| Papilloma, Inverted | 1 | 2015 | 6 | 0.130 |
Why?
|
| Eustachian Tube | 1 | 2015 | 9 | 0.130 |
Why?
|
| Risk Factors | 5 | 2020 | 5416 | 0.130 |
Why?
|
| Premedication | 2 | 1994 | 54 | 0.130 |
Why?
|
| Respiratory System | 2 | 2011 | 116 | 0.130 |
Why?
|
| Administration, Oral | 4 | 2006 | 684 | 0.130 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2015 | 24 | 0.130 |
Why?
|
| Polyps | 1 | 2015 | 28 | 0.130 |
Why?
|
| Fever | 1 | 2015 | 125 | 0.130 |
Why?
|
| Airway Management | 1 | 2015 | 46 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2020 | 1804 | 0.130 |
Why?
|
| Biomarkers | 3 | 2017 | 1718 | 0.130 |
Why?
|
| Ancillary Services, Hospital | 1 | 2014 | 1 | 0.130 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 99 | 0.130 |
Why?
|
| User-Computer Interface | 1 | 2016 | 185 | 0.120 |
Why?
|
| Oxygen | 1 | 2019 | 726 | 0.120 |
Why?
|
| Decision Making | 1 | 2020 | 642 | 0.120 |
Why?
|
| Radiography | 2 | 2014 | 813 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2013 | 2261 | 0.120 |
Why?
|
| Phenotype | 3 | 2020 | 2377 | 0.120 |
Why?
|
| Body Temperature | 3 | 2005 | 124 | 0.120 |
Why?
|
| United States | 7 | 2023 | 6665 | 0.120 |
Why?
|
| Rhinometry, Acoustic | 1 | 2014 | 3 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 241 | 0.120 |
Why?
|
| Smoking | 2 | 2016 | 609 | 0.120 |
Why?
|
| Prednisone | 1 | 2014 | 258 | 0.120 |
Why?
|
| Antigens, Fungal | 1 | 2013 | 6 | 0.120 |
Why?
|
| Otitis Media | 2 | 2003 | 18 | 0.120 |
Why?
|
| Foreign Bodies | 2 | 2009 | 63 | 0.110 |
Why?
|
| Anesthetics, Intravenous | 1 | 2013 | 41 | 0.110 |
Why?
|
| Injections, Intraocular | 1 | 2013 | 5 | 0.110 |
Why?
|
| Olopatadine Hydrochloride | 1 | 2013 | 6 | 0.110 |
Why?
|
| Reference Values | 2 | 2013 | 674 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2013 | 256 | 0.110 |
Why?
|
| Operative Time | 1 | 2013 | 127 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 2261 | 0.110 |
Why?
|
| Fungi | 1 | 2013 | 65 | 0.110 |
Why?
|
| Phleum | 1 | 2012 | 2 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 1753 | 0.110 |
Why?
|
| Immune System | 1 | 1993 | 93 | 0.110 |
Why?
|
| Mites | 1 | 2012 | 16 | 0.110 |
Why?
|
| Cost of Illness | 3 | 2015 | 150 | 0.110 |
Why?
|
| Anesthetics, Inhalation | 1 | 2013 | 95 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1621 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2013 | 117 | 0.110 |
Why?
|
| Dust | 1 | 2012 | 26 | 0.110 |
Why?
|
| Skin Temperature | 2 | 2003 | 14 | 0.100 |
Why?
|
| Bronchi | 3 | 2012 | 229 | 0.100 |
Why?
|
| Tumor Necrosis Factors | 1 | 2011 | 14 | 0.100 |
Why?
|
| Bodily Secretions | 1 | 2011 | 3 | 0.100 |
Why?
|
| Ovalbumin | 3 | 2006 | 109 | 0.100 |
Why?
|
| Antigens, Plant | 1 | 2011 | 14 | 0.100 |
Why?
|
| Epigenomics | 1 | 2012 | 100 | 0.100 |
Why?
|
| Ioxaglic Acid | 1 | 2011 | 7 | 0.100 |
Why?
|
| Neck | 2 | 2006 | 100 | 0.100 |
Why?
|
| Time Factors | 8 | 2006 | 5209 | 0.100 |
Why?
|
| Airway Resistance | 5 | 1999 | 69 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 581 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2011 | 165 | 0.100 |
Why?
|
| Ribonucleases | 2 | 2001 | 92 | 0.100 |
Why?
|
| Hydroxyapatites | 1 | 2010 | 7 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 272 | 0.090 |
Why?
|
| Molar | 1 | 2010 | 21 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 379 | 0.090 |
Why?
|
| Oral Surgical Procedures | 1 | 2010 | 19 | 0.090 |
Why?
|
| Colony Count, Microbial | 2 | 2008 | 46 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 930 | 0.090 |
Why?
|
| Probability | 2 | 2008 | 355 | 0.090 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 26 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2007 | 1313 | 0.090 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 41 | 0.090 |
Why?
|
| Algorithms | 3 | 2015 | 1830 | 0.090 |
Why?
|
| Biopsy | 3 | 1999 | 1161 | 0.090 |
Why?
|
| Deafness | 1 | 2009 | 47 | 0.090 |
Why?
|
| Cochlear Implantation | 1 | 2009 | 31 | 0.090 |
Why?
|
| Neutrophils | 5 | 2001 | 307 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 301 | 0.090 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 43 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1849 | 0.080 |
Why?
|
| Aged | 10 | 2016 | 18402 | 0.080 |
Why?
|
| Flow Cytometry | 4 | 2014 | 679 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 468 | 0.080 |
Why?
|
| Fundoplication | 1 | 2009 | 72 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1019 | 0.080 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1169 | 0.080 |
Why?
|
| Epidural Abscess | 1 | 2008 | 3 | 0.080 |
Why?
|
| Turbinates | 3 | 2015 | 11 | 0.080 |
Why?
|
| Phenoxybenzamine | 2 | 2005 | 15 | 0.080 |
Why?
|
| Urban Health | 1 | 2008 | 55 | 0.080 |
Why?
|
| Eyebrows | 1 | 2008 | 10 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2005 | 35 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 1531 | 0.080 |
Why?
|
| Foot | 3 | 2003 | 50 | 0.080 |
Why?
|
| Lacrimal Apparatus | 1 | 2008 | 11 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2010 | 751 | 0.080 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 29 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 1 | 2008 | 35 | 0.080 |
Why?
|
| Vocal Cord Paralysis | 1 | 2007 | 26 | 0.080 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 53 | 0.080 |
Why?
|
| Orbit | 1 | 2008 | 37 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 1565 | 0.080 |
Why?
|
| Mouth Mucosa | 1 | 2008 | 67 | 0.080 |
Why?
|
| Craniotomy | 1 | 2008 | 88 | 0.080 |
Why?
|
| Parasympathetic Nervous System | 3 | 2001 | 33 | 0.080 |
Why?
|
| Receptors, Histamine H1 | 2 | 2000 | 8 | 0.080 |
Why?
|
| Kartagener Syndrome | 1 | 2007 | 1 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 89 | 0.080 |
Why?
|
| Urban Population | 1 | 2008 | 213 | 0.080 |
Why?
|
| Histamine Antagonists | 2 | 2018 | 12 | 0.070 |
Why?
|
| Hypopharynx | 1 | 2006 | 8 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2006 | 74 | 0.070 |
Why?
|
| Videotape Recording | 1 | 2006 | 47 | 0.070 |
Why?
|
| Mice | 8 | 2008 | 11352 | 0.070 |
Why?
|
| Incidence | 1 | 2011 | 1576 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2008 | 326 | 0.070 |
Why?
|
| Muscarinic Agonists | 2 | 1996 | 23 | 0.070 |
Why?
|
| Disease Management | 2 | 2020 | 327 | 0.070 |
Why?
|
| Water | 2 | 2005 | 275 | 0.070 |
Why?
|
| Fluoroscopy | 1 | 2006 | 119 | 0.070 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2006 | 24 | 0.070 |
Why?
|
| Sensation | 1 | 2006 | 45 | 0.070 |
Why?
|
| Nasal Surgical Procedures | 2 | 2016 | 8 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2006 | 86 | 0.070 |
Why?
|
| E-Selectin | 2 | 1996 | 30 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2008 | 244 | 0.070 |
Why?
|
| Head | 1 | 2006 | 132 | 0.070 |
Why?
|
| Prevalence | 3 | 2020 | 1239 | 0.070 |
Why?
|
| Cystic Fibrosis | 3 | 1995 | 112 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2009 | 3636 | 0.060 |
Why?
|
| Physical Examination | 2 | 2018 | 149 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2021 | 153 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 370 | 0.060 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 115 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1673 | 0.060 |
Why?
|
| Referral and Consultation | 2 | 2020 | 326 | 0.060 |
Why?
|
| Mometasone Furoate | 3 | 2011 | 18 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2005 | 293 | 0.060 |
Why?
|
| Therapeutic Irrigation | 2 | 2002 | 60 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 451 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1376 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1920 | 0.060 |
Why?
|
| Basophils | 2 | 1994 | 25 | 0.060 |
Why?
|
| Suppuration | 1 | 2003 | 9 | 0.060 |
Why?
|
| Cephalexin | 1 | 2003 | 6 | 0.060 |
Why?
|
| Bronchoscopy | 1 | 2005 | 152 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 53 | 0.060 |
Why?
|
| Kinetics | 2 | 1999 | 1513 | 0.060 |
Why?
|
| Administration, Topical | 2 | 2008 | 95 | 0.060 |
Why?
|
| Tryptases | 1 | 2002 | 12 | 0.060 |
Why?
|
| Cell Separation | 2 | 2014 | 196 | 0.060 |
Why?
|
| Pruritus | 1 | 2002 | 26 | 0.060 |
Why?
|
| Epithelial Cells | 2 | 2012 | 669 | 0.060 |
Why?
|
| Community-Acquired Infections | 1 | 2003 | 63 | 0.060 |
Why?
|
| Cultural Diversity | 1 | 2023 | 51 | 0.060 |
Why?
|
| Demography | 1 | 2023 | 177 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2006 | 812 | 0.060 |
Why?
|
| Brain | 1 | 2013 | 2216 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2022 | 117 | 0.050 |
Why?
|
| Climate Change | 1 | 2023 | 42 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2002 | 1195 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 454 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2023 | 123 | 0.050 |
Why?
|
| Neurosurgery | 1 | 2023 | 84 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6501 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2002 | 287 | 0.050 |
Why?
|
| Supine Position | 1 | 2001 | 30 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 408 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 567 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2006 | 1924 | 0.050 |
Why?
|
| Neuropeptides | 2 | 1999 | 112 | 0.050 |
Why?
|
| Skull Base | 1 | 2022 | 47 | 0.050 |
Why?
|
| Lidocaine | 3 | 2003 | 63 | 0.050 |
Why?
|
| Respiratory Mucosa | 2 | 2018 | 88 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2001 | 80 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 31 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2001 | 34 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2001 | 49 | 0.050 |
Why?
|
| Antibody Specificity | 2 | 1997 | 129 | 0.050 |
Why?
|
| Hearing | 1 | 2021 | 59 | 0.050 |
Why?
|
| General Surgery | 1 | 2023 | 228 | 0.050 |
Why?
|
| Internationality | 1 | 2021 | 69 | 0.050 |
Why?
|
| Body Temperature Regulation | 1 | 2000 | 56 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2000 | 17 | 0.050 |
Why?
|
| Atrophy | 1 | 2001 | 117 | 0.050 |
Why?
|
| Educational Status | 1 | 2021 | 188 | 0.050 |
Why?
|
| Workload | 1 | 2001 | 128 | 0.050 |
Why?
|
| Reaction Time | 1 | 2001 | 309 | 0.050 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 4 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2000 | 65 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 30 | 0.050 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 32 | 0.050 |
Why?
|
| Masks | 1 | 2000 | 29 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2705 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 48 | 0.050 |
Why?
|
| Nose Neoplasms | 1 | 1999 | 31 | 0.040 |
Why?
|
| Checklist | 1 | 2020 | 57 | 0.040 |
Why?
|
| Antibody Formation | 3 | 1997 | 171 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 193 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2001 | 178 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1990 | 0.040 |
Why?
|
| Capsaicin | 2 | 1999 | 44 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 141 | 0.040 |
Why?
|
| Leukocytes | 2 | 2001 | 202 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2000 | 140 | 0.040 |
Why?
|
| Parents | 1 | 2021 | 272 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1998 | 66 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1998 | 38 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 59 | 0.040 |
Why?
|
| Immunization | 1 | 1998 | 158 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 2018 | 55 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 334 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 752 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 1139 | 0.040 |
Why?
|
| Tachyphylaxis | 2 | 1994 | 14 | 0.040 |
Why?
|
| Peroxidases | 1 | 1997 | 34 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 216 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 1997 | 14 | 0.040 |
Why?
|
| Bias | 1 | 2017 | 127 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 1996 | 18 | 0.040 |
Why?
|
| Epithelium | 1 | 1998 | 319 | 0.040 |
Why?
|
| Allergy and Immunology | 1 | 2016 | 12 | 0.040 |
Why?
|
| Otolaryngologists | 1 | 2016 | 4 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 1996 | 16 | 0.040 |
Why?
|
| Respiration | 2 | 2000 | 262 | 0.040 |
Why?
|
| Albuterol | 1 | 1997 | 35 | 0.040 |
Why?
|
| Th2 Cells | 2 | 2012 | 146 | 0.040 |
Why?
|
| Probiotics | 1 | 2018 | 81 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 3 | 2006 | 1047 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 72 | 0.040 |
Why?
|
| Nasal Sprays | 1 | 2016 | 9 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 1996 | 94 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 1997 | 188 | 0.040 |
Why?
|
| Prostaglandins | 1 | 1996 | 43 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 636 | 0.040 |
Why?
|
| Mandibular Advancement | 1 | 2016 | 6 | 0.030 |
Why?
|
| Oropharynx | 1 | 2016 | 15 | 0.030 |
Why?
|
| Sphenoid Sinus | 1 | 1995 | 6 | 0.030 |
Why?
|
| Internal Fixators | 1 | 2016 | 14 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 220 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 674 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2016 | 31 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2016 | 91 | 0.030 |
Why?
|
| Peptide Hydrolases | 2 | 1992 | 100 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2018 | 296 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 2 | 1994 | 55 | 0.030 |
Why?
|
| Acupuncture Therapy | 1 | 2015 | 11 | 0.030 |
Why?
|
| Trachea | 1 | 1996 | 293 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 1996 | 144 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1994 | 71 | 0.030 |
Why?
|
| Physician's Role | 1 | 2016 | 179 | 0.030 |
Why?
|
| Mucocele | 1 | 1994 | 4 | 0.030 |
Why?
|
| Models, Biological | 2 | 2008 | 1749 | 0.030 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 38 | 0.030 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1994 | 8 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 304 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2015 | 111 | 0.030 |
Why?
|
| Face | 1 | 1995 | 114 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1994 | 127 | 0.030 |
Why?
|
| Cell Movement | 1 | 1998 | 758 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2014 | 48 | 0.030 |
Why?
|
| Mucus | 1 | 1994 | 19 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 130 | 0.030 |
Why?
|
| Triamcinolone Acetonide | 1 | 1993 | 8 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2014 | 97 | 0.030 |
Why?
|
| Platelet Activating Factor | 1 | 1994 | 53 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2015 | 133 | 0.030 |
Why?
|
| Patient Care | 2 | 2004 | 100 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 864 | 0.030 |
Why?
|
| Guidelines as Topic | 2 | 2004 | 162 | 0.030 |
Why?
|
| Diphenhydramine | 1 | 1993 | 17 | 0.030 |
Why?
|
| Cold Temperature | 1 | 1993 | 157 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1995 | 226 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 247 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 1993 | 76 | 0.030 |
Why?
|
| Paper | 1 | 1992 | 10 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 166 | 0.030 |
Why?
|
| Filtration | 1 | 1992 | 25 | 0.030 |
Why?
|
| Linear Models | 1 | 1994 | 421 | 0.030 |
Why?
|
| Blood Circulation | 1 | 2012 | 29 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 572 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1996 | 559 | 0.030 |
Why?
|
| Administration, Sublingual | 1 | 2012 | 5 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1992 | 141 | 0.030 |
Why?
|
| Immersion | 2 | 2003 | 21 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2012 | 71 | 0.030 |
Why?
|
| Pediatrics | 1 | 2016 | 344 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2008 | 3092 | 0.030 |
Why?
|
| Up-Regulation | 1 | 1994 | 712 | 0.030 |
Why?
|
| Hypersensitivity, Immediate | 1 | 1992 | 62 | 0.030 |
Why?
|
| Leukotrienes | 1 | 1991 | 20 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 594 | 0.030 |
Why?
|
| Eosinophil Granule Proteins | 2 | 2001 | 20 | 0.030 |
Why?
|
| Europe | 1 | 2012 | 309 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 1078 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 102 | 0.020 |
Why?
|
| Omalizumab | 1 | 2010 | 8 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 30 | 0.020 |
Why?
|
| Agnosia | 1 | 2010 | 5 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 458 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 22 | 0.020 |
Why?
|
| Alveolar Bone Loss | 1 | 2010 | 20 | 0.020 |
Why?
|
| Blood Proteins | 2 | 2001 | 144 | 0.020 |
Why?
|
| Bacteria | 1 | 2014 | 447 | 0.020 |
Why?
|
| Hydroxyzine | 1 | 1989 | 7 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1989 | 16 | 0.020 |
Why?
|
| Cetirizine | 1 | 1989 | 12 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 105 | 0.020 |
Why?
|
| Audiology | 1 | 2009 | 2 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2010 | 91 | 0.020 |
Why?
|
| Language Development Disorders | 1 | 2009 | 24 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 1989 | 48 | 0.020 |
Why?
|
| Education | 1 | 2009 | 58 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2009 | 53 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 272 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2009 | 87 | 0.020 |
Why?
|
| Calcium Channels | 1 | 1989 | 182 | 0.020 |
Why?
|
| Serotonin | 1 | 1989 | 218 | 0.020 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2008 | 4 | 0.020 |
Why?
|
| Pneumocephalus | 1 | 2008 | 10 | 0.020 |
Why?
|
| Frontal Sinus | 1 | 2008 | 7 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 372 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2009 | 227 | 0.020 |
Why?
|
| Dopamine | 1 | 1989 | 275 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 999 | 0.020 |
Why?
|
| Esophagitis | 1 | 2008 | 42 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 78 | 0.020 |
Why?
|
| Random Allocation | 2 | 2001 | 332 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2818 | 0.020 |
Why?
|
| Drainage | 1 | 2008 | 157 | 0.020 |
Why?
|
| Lactoferrin | 2 | 1997 | 11 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 394 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2005 | 31 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2006 | 321 | 0.020 |
Why?
|
| Skin | 1 | 2008 | 554 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 102 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2006 | 240 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 916 | 0.010 |
Why?
|
| Observer Variation | 1 | 2004 | 602 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 197 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2003 | 104 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 76 | 0.010 |
Why?
|
| Receptors, CCR3 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Chemokine CCL11 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Air Conditioning | 1 | 2001 | 6 | 0.010 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 34 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2001 | 145 | 0.010 |
Why?
|
| Acoustics | 1 | 2001 | 51 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2001 | 164 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2001 | 129 | 0.010 |
Why?
|
| Neurokinin A | 1 | 1999 | 12 | 0.010 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1999 | 38 | 0.010 |
Why?
|
| Substance P | 1 | 1999 | 61 | 0.010 |
Why?
|
| Nasopharynx | 1 | 1999 | 47 | 0.010 |
Why?
|
| Hospitalization | 1 | 2004 | 848 | 0.010 |
Why?
|
| Eosinophil Peroxidase | 1 | 1997 | 14 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 39 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1997 | 102 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1997 | 76 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1996 | 130 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 3967 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 2468 | 0.010 |
Why?
|
| Calcium | 1 | 2001 | 1156 | 0.010 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 1996 | 99 | 0.010 |
Why?
|
| Jaw Neoplasms | 1 | 1995 | 5 | 0.010 |
Why?
|
| Facial Neoplasms | 1 | 1995 | 25 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1995 | 42 | 0.010 |
Why?
|
| Tears | 1 | 1994 | 7 | 0.010 |
Why?
|
| Soft Tissue Infections | 1 | 1995 | 26 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 1981 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1995 | 235 | 0.010 |
Why?
|
| Anesthesia | 1 | 1996 | 164 | 0.010 |
Why?
|
| Tosylarginine Methyl Ester | 1 | 1994 | 5 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1994 | 40 | 0.010 |
Why?
|
| Acute-Phase Reaction | 1 | 1994 | 16 | 0.010 |
Why?
|
| Phospholipases A | 1 | 1994 | 45 | 0.010 |
Why?
|
| Radioallergosorbent Test | 1 | 1993 | 8 | 0.010 |
Why?
|
| Frontal Sinusitis | 1 | 1993 | 2 | 0.010 |
Why?
|
| Sphenoid Sinusitis | 1 | 1993 | 2 | 0.010 |
Why?
|
| Ethmoid Sinusitis | 1 | 1993 | 4 | 0.010 |
Why?
|
| Anesthesia, Local | 1 | 1993 | 27 | 0.010 |
Why?
|
| Cephalometry | 1 | 1993 | 50 | 0.010 |
Why?
|
| Tuberculosis | 1 | 1995 | 110 | 0.010 |
Why?
|
| Nasal Septum | 1 | 1993 | 28 | 0.010 |
Why?
|
| Seasons | 1 | 1993 | 223 | 0.010 |
Why?
|
| Kinins | 1 | 1992 | 31 | 0.010 |
Why?
|
| Proteins | 1 | 1994 | 777 | 0.010 |
Why?
|